Jiding Pharma

Jiding Pharma is a clinical-stage biotechnology company headquartered in Shanghai, China, specializing in the discovery and development of innovative small molecule therapeutics for oncology and autoimmune diseases. The company leverages its proprietary drug discovery platform to target difficult-to-drug proteins, with a primary focus on the RAS signaling pathway. Its lead candidate, JD-001, is a potent and selective KRAS G12C inhibitor currently undergoing clinical evaluation for the treatment of advanced solid tumors. Jiding Pharma is backed by prominent life science investors, including Qiming Venture Partners and Lilly Asia Ventures, and aims to address significant unmet medical needs through precision medicine. The company's pipeline also includes promising programs targeting SHP2 and KRAS G12D, reflecting its commitment to overcoming cancer resistance.